Q2 2023
Released Aug 14, 2023, before the open
10-Q filed Aug 14, 2023, 45 days after period end · 0001789769-23-000085
Q2 2023 · 10-Q
Revenue—
Net Income-$18.66M-$18.66M N/M vs Q2 2022N/M vs Q1 2023
EPS Diluted-$2.87-$2.87 N/M vs Q2 2022N/M vs Q1 2023
Operating Income-$20,987,000N/M
Operating Cash Flowderived-$19,560,000N/M
Free Cash Flowderived-$26,540,000N/M
What the release said
The release
Same quarter
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Revenue | — | — | $0.00 | $42.00K |
| Net Income | -$18.66M | -$58.99M | -$35.31M | -$9.20M |
| EPS Diluted | -$2.87 | -$0.46 | -$0.27 | -$0.55 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Instil Bio, Inc. · CIK 1789769 · Engraved from SEC EDGAR